Home/ Stocks/ RARE

Ultragenyx Pharmaceutical Inc.

RARE XNAS

$26.12 -0.53 (-2.03%) ▼ 15-min delayed

Open

$26.05

High

$26.67

Low

$25.93

Volume

1.56M

Market Cap

$2.57B

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 1.4K Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$136.00M	$-185,000,000	$-1.84
FY 2025	$673.00M	$-575,000,000	$-5.83
Q3 2025	$159.93M	$-180,413,000	$-1.81
Q2 2025	$166.50M	$-114,951,000	$-1.17

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for RARE yet. Check out our latest market news or earnings calendar.

Get RARE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Ultragenyx Pharmaceutical Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.